Zimmer Biomet Holdings, INC.: insider trades · United States · SEC (Form 4)

About Zimmer Biomet Holdings, INC.

Zimmer Biomet Holdings, Inc. (ticker: ZBH) is a global medical technology company focused on orthopedics and musculoskeletal solutions. The stock is listed on the NYSE in the United States, and the company is headquartered in Warsaw, Indiana. Its roots date back to 1927, when Zimmer Manufacturing Company was founded in Warsaw. Zimmer Biomet became an independent public company in 2001 and later expanded materially through the 2015 acquisition of Biomet, which led to the current corporate name. The company designs, manufactures and markets a broad portfolio of orthopedic implants and related devices, with core franchises in hips, knees and shoulders, as well as products for extremities, trauma, craniomaxillofacial and thoracic applications, bone cement, surgical products, and integrated digital and robotic technologies. Its offering includes robotic-assisted surgery platforms, navigation tools, software-enabled workflows and next-generation implant designs. For investors, Zimmer Biomet is best viewed as a broad-based orthopedic platform rather than a single-product company: it serves orthopedic surgeons, hospitals, ambulatory surgery centers, distributors and purchasing groups across multiple geographies. From a competitive standpoint, the company benefits from a long operating history, a recognized brand, a large installed customer base and a meaningful global manufacturing and R&D footprint. Zimmer Biomet operates roughly 300 facilities worldwide, with major activities in the United States, Switzerland, Ireland and China. Its annual report indicates that the United States accounts for about 58% of revenue, making the U.S. market central to both its commercial performance and its ongoing transformation of its domestic go-to-market model. Recent developments have been strategically important. Zimmer Biomet reported 2025 net sales of $8.232 billion, supported by market growth, new product introductions and the acquisition of Paragon 28. In 2025, it also completed the acquisition of Monogram Technologies, expanding its robotics and digital ecosystem with a pathway toward more autonomous orthopedic technology. In early 2026, the company highlighted the launch and expansion of ROSA Knee with OptimiZe, together with new regulatory milestones in hip and knee implants. Overall, the investment case combines a defensive elective-procedure profile, strong innovation intensity and targeted M&A aimed at faster-growing orthopedic subsegments.